Avara Pharmaceutical Services’ facility in Liscate, Italy, which provides sterile manufacturing, fill-finish, and packaging services for supply to European, U.S., Canadian, and Latin American markets, recently hosted the U.S. FDA as part of a Pre-Approval Inspection for a new client’s product to be manufactured in the small volume parenterals department. In addition, a routine GMP inspection for the lyophilization department was also conducted. FDA recommended the renewal of the facility license and approval of the new product as well.
 
In other news, Avara Liscate has appointed a new manufacturing director to the leadership team. Vincenzo Riello joins the Avara Liscate team with a wealth of experience in sterile manufacturing gained over many years in large pharma organizations as well as contract development and manufacturing organizations (CDMOs). Marco Scanziani, who held the position prior, will be Avara Liscate’s new customer relationship leader and will apply his 15 years of manufacturing and quality experience to leading the project management function in Avara Liscate.